OOIR: Observatory of International Research

Papers

(The TQCC of Applied Health Economics and Health Policy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
The Danish EQ-5D-5L Value Set: A Hybrid Model Using cTTO and DCE Data	91
Willingness to Pay for a COVID-19 Vaccine	89
The Role of Mental Health on Workplace Productivity: A Critical Review of the Literature	41
Disease-Specific Out-of-Pocket Payments, Catastrophic Health Expenditure and Impoverishment Effects in India: An Analysis of National Health Survey Data	33
Analysing the Efficiency of Health Systems: A Systematic Review of the Literature	32
Health Financing in Sub-Saharan Africa: From Analytical Frameworks to Empirical Evaluation	31
Towards a Broader Assessment of Value in Vaccines: The BRAVE Way Forward	30
How Many Intensive Care Beds are Justifiable for Hospital Pandemic Preparedness? A Cost-effectiveness Analysis for COVID-19 in Germany	29
The Effects of School Closures on COVID-19: A Cross-Country Panel Analysis	28
Value and Price of Multi-indication Cancer Drugs in the USA, Germany, France, England, Canada, Australia, and Scotland	28
Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options	27
Comparison of Prices and Affordability of Cancer Medicines in 16 Countries in Europe and Latin America	25
Population Norms for SF-6Dv2 and EQ-5D-5L in China	22
Costs of Illness of Spinal Muscular Atrophy: A Systematic Review	21
The Indirect Cost Burden of Cancer Care in Canada: A Systematic Literature Review	21
Translating Research to Policy: Setting Provider Payment Rates for Strategic Purchasing under India's National Publicly Financed Health Insurance Scheme	20
COVID-19 Vaccine Demand and Financial Incentives	20
How Effective is Marginal Healthcare Expenditure? New Evidence from England for 2003/04 to 2012/13	20
The Sandbox Approach and its Potential for Use in Health Technology Assessment: A Literature Review	20
Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives	19
Incidence of Catastrophic Health Expenditure and Its Determinants in Cancer Patients: A Systematic Review and Meta-analysis	19
‘What You See is All There is’: The Importance of Heuristics in Cost-Benefit Analysis (CBA) and Social Return on Investment (SROI) in the Evaluation of Public Health Interventions	19
Family Spillover Effects: Are Economic Evaluations Misrepresenting the Value of Healthcare Interventions to Society?	17
Using Constrained Optimization for the Allocation of COVID-19 Vaccines in the Philippines	17
EQ-5D-5L Health-State Values for the Mexican Population	15

The Health and Productivity Burden of Depression in South Korea	15
Supply-Side Cost-Effectiveness Thresholds: Questions for Evidence-Based Policy	14
Which Criteria are Considered and How are They Evaluated in Health Technology Assessments? A Review of Methodological Guidelines Used in Western and Asian Countries	14
Modelling the Future Clinical and Economic Burden of Antimicrobial Resistance: The Feasibility and Value of Models to Inform Policy	13
Preferences for Medical Consultations from Online Providers: Evidence from a Discrete Choice Experiment in the United Kingdom	13
Economic Evaluations of Preventive Interventions for Dental Caries and Periodontitis: A Systematic Review	13
Discrete Choice Experiments in Health State Valuation: A Systematic Review of Progress and New Trends	12
EQ-5D-5L Population Norms for Italy	12
Cost-effectiveness of Interventions for Chronic Fatigue Syndrome or Myalgic Encephalomyelitis: A Systematic Review of Economic Evaluations	12
National Methodological Guidelines to Conduct Budget Impact Analysis for Health Technology Assessment in India	12
Methodological Note: Reporting Deterministic versus Probabilistic Results of Markov, Partitioned Survival and Other Non-Linear Models	12
Cost Effectiveness of Case Detection Strategies for the Early Detection of COPD	11
Centralised Pharmaceutical Procurement: Learnings from Six European Countries	11
Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments	11
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	11
Korean Guidelines for Pharmacoeconomic Evaluations: Updates in the Third Version	11
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment	10
Deterministic and Probabilistic Analysis of a Simple Markov Model: How Different Could They Be?	10
The Impact of Financing Health Services on Income Inequality in an Unequal Society: The Case of South Africa	10
Effect of Competition on Generic Drug Prices	10
Allocating Public Spending Efficiently: Is There a Need for a Better Mechanism to Inform Decisions in the UK and Elsewhere?	10
Approaches to Measure Efficiency in Primary Care: A Systematic Literature Review	10
Development of an Instrument for the Assessment of Health-Related Multi-sectoral Resource Use in Europe: The PECUNIA RUM	9
Consumers' Preferences and Willingness to Pay for Personalised Nutrition	9
Can the UK ‘Netflix’ Payment Model Boost the Antibacterial Pipeline?	9
Drug Repurposing of Generic Drugs: Challenges and the Potential Role for Government	9
Cost-Utility Analysis of Discontinuing Antidepressants in England Primary Care Patients Compared with Long-Term Maintenance: The ANTLER Study	8
Systematic Literature Review of Guidelines on Budget Impact Analysis for Health Technology Assessment	8
Correction to: Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) Statement: Updated Reporting Guidance for Health Economic Evaluations	8
Information Asymmetry in Hospitals: Evidence of the Lack of Cost Awareness in Clinicians	8
The Cost Effectiveness of Taxation of Sugary Foods and Beverages: A Systematic Review of Economic Evaluations	7
Economic Evaluation Evidence for Resource-Allocation Decision Making: Bridging the Gap for Local Decision Makers Using English Case Studies	7
Valuation of Costs in Health Economics During Financial and Economic Crises: A Case Study from Lebanon	7
Cost-Effectiveness Analysis of Stockholm 3 Testing Compared to PSA as the Primary Blood Test in the Prostate Cancer Diagnostic Pathway: A Decision Tree Approach	7
Global Pull Incentives for Better Antibacterials: The UK Leads the Way	7
Preferred Attributes of Care Pathways for Obstructive Sleep Apnoea from the Perspective of Diagnosed Patients and High-Risk Individuals: A Discrete Choice Experiment	6
Prescription Drug Monitoring Programs and Opioid Prescriptions for Disability Conditions	6
Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance	6
How Responsive is Mortality to Locally Administered Healthcare Expenditure? Estimates for England for 2014/15	6
Opioid Prescribing in Canada following the Legalization of Cannabis: A Clinical and Economic Time-Series Analysis	6
Economic Consequences of Anti-HCV Treatment of Patients Diagnosed Through Screening in Italy: A Prospective Modelling Analysis	6
Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden	6
What Policy Approaches Were Effective in Reducing Catastrophic Health Expenditure? A Systematic Review of Studies from Multiple Countries	6
UroLift for Treating Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A NICE Medical Technology Guidance Update	6
Are Estimates of the Health Opportunity Cost Being Used to Draw Conclusions in Published Cost-Effectiveness Analyses? A Scoping Review in Four Countries	6
Estimating the Health Effects of Expansions in Health Expenditure in Indonesia: A Dynamic Panel Data Approach	6
Cost Effectiveness of Pharmacological Management for Osteoarthritis: A Systematic Review	6
Authors’ Reply to Sprengholz and Betsch: “Willingness to Pay for a COVID-19 Vaccine”	6
Herd Immunity Effects in Cost-Effectiveness Analyses among Low- and Middle-Income Countries	6
Cost Effectiveness of Ribociclib and Palbociclib in the Second-Line Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer in Post-Menopausal Indian Women	6

Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C	6
What Features of Fertility Treatment do Patients Value? Price Elasticity and Willingness-to-Pay Values from a Discrete Choice Experiment	6
myCOPD App for Managing Chronic Obstructive Pulmonary Disease: A NICE Medical Technology Guidance for a Digital Health Technology	6
Pricing and Reimbursement of Patent-Protected Medicines: Challenges and Lessons from South-Eastern Europe	6